Interleukin-11 to Enter Phase III

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 7
Volume 4
Issue 7

CAMBRIDGE, Mass--In a phase II study, Genetics Institute's recombinant human interleukin-11 (rhIL-11) restored platelets in throm-bocytopenic patients undergoing cancer chemotherapy to the extent that significantly fewer rhIL-11 treated patients required platelet transfusions, compared to placebo.

CAMBRIDGE, Mass--In a phase II study, Genetics Institute's recombinanthuman interleukin-11 (rhIL-11) restored platelets in throm-bocytopenicpatients undergoing cancer chemotherapy to the extent that significantlyfewer rhIL-11 treated patients required platelet transfusions,compared to placebo.

Based on this favorable outcome, the company plans to begin aphase III study by the end of this year.

Articles in this issue
ODAC Recommends Accelerated FDA Approval of Ethyol for Cytoprotection
House Panel Holds Hearing on Self-Referral
Health-Related Legislation
Mitoguazone Appears Promising in HIV-Associated Refractory NHL
Responses to Anti-HER2 MoAb Seen
NCI Committed to Increasing Minority Participation in Clinical Trials
MoAb May Improve Detection of Colon And Rectal Cancer
Zeneca Files NDA for Arimidex
Cord Blood is Used as Source of Stem Cells for Pediatric Transplantation
Gemcitabine/Cisplatin Shows Good Response Rate And Favorable Toxicity Profile in Advanced NSCLC
HCFA Needs to Do More to Prevent Medicare/Medicaid Fraud and Abuse
M.D. Anderson Holds First Cancer Meeting in Spanish
Molecular Markers Predict Clinical Outcome
NCAB Has Concerns About Future of Clinical Research
IP Interleukin-2 Shows Durable Responses in Ovarian Cancer
Recent Videos
The mechanism of action for daraxonrasib inhibits effectors and signaling while forming a relatively unstable tri-complex with codon 12 mutations.
4 experts are featured in this series.
6 experts are featured in this series.
6 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Related Content
Real-world data show that closer monitoring may be necessary for patients with relapsed/refractory multiple myeloma and baseline renal impairment.

CAR T Therapy Shows Similar Efficacy, Safety in Multiple Myeloma Subgroups

Russ Conroy
February 2nd 2025
Article

Real-world data show that closer monitoring may be necessary for patients with relapsed/refractory multiple myeloma and baseline renal impairment.

Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.

Conducting Early Phase Trials of Promising Treatments in Neuro-Oncology

Shwetal Mehta, PhD
January 27th 2025
Podcast

Shwetal Mehta, PhD, emphasizes her institution’s patient-focused and scientifically rigorous philosophy when developing new therapies in brain cancer.

Data support cetuximab/radiotherapy as a suitable option in carefully selected patients with HPV-negative squamous cell carcinoma of the head and neck.

Cetuximab/Radiation Improves DFS in Locally Advanced SCCHN

Russ Conroy
February 1st 2025
Article

Data support cetuximab/radiotherapy as a suitable option in carefully selected patients with HPV-negative squamous cell carcinoma of the head and neck.

Michael P. Bogenschutz, MD, discusses the efficacy, safety, implementation, and future research of psilocybin for cancer-related psychological events.

Psilocybin May Help Address Cancer-Related Psychological Concerns

Michael P. Bogenschutz, MD
January 20th 2025
Podcast

Michael P. Bogenschutz, MD, discusses the efficacy, safety, implementation, and future research of psilocybin for cancer-related psychological events.

Incorporating frailty evaluation into practice may alter clinical decision-making for preoperative planning and patient counseling for gynecologic surgery.

Frailty Confers Worse Recovery Outcomes After Gynecologic Surgery

Roman Fabbricatore
January 31st 2025
Article

Incorporating frailty evaluation into practice may alter clinical decision-making for preoperative planning and patient counseling for gynecologic surgery.

Azenosertib Monotherapy Yields Encouraging Responses in Cyclin E1+ PROC

Azenosertib Monotherapy Yields Encouraging Responses in Cyclin E1+ PROC

Tim Cortese
January 31st 2025
Article

Results from the ZN-c3-001, MAMMOTH, and DENALI trials demonstrated meaningful ORRs with azenosertib in platinum-resistant ovarian cancer.